Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Efficacy and Safety Study of Linagliptin (5 mg Administered Orally Once Daily) Over 24 Weeks, in Drug naïve or Previously Treated Type 2 Diabetic Patients With Insufficient Glycaemic Control

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Placebo
Drug: Linagliptin

First Posted Date: 2010-10-05

Last Posted Date: 2016-08-25

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 300

Registration Number: NCT01214239

Locations: 🇵🇭
1218.66.63001 Boehringer Ingelheim Investigational Site, Marikina, Philippines
🇵🇭
1218.66.63002 Boehringer Ingelheim Investigational Site, San Juan, Philippines
🇨🇳
1218.66.86007 Boehringer Ingelheim Investigational Site, Beijing, China

and more 16 locations

Multiple Dose Bioequivalence Study of Pramipexole Extended Release in Chinese Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: pramipexole extended release
Drug: pramipexole immediate release

First Posted Date: 2010-10-04

Last Posted Date: 2014-06-27

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 24

Registration Number: NCT01214109

Locations: 🇨🇳
248.665.86002 Boehringer Ingelheim Investigational Site, Beijing, China

Bioavailability of a Fixed Dose Combination Tablet With Empagliflozin (BI 10773) and Metformin Compared With the Monocomponents and Effect of Food on Bioavailability

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2

First Posted Date: 2010-09-29

Last Posted Date: 2015-08-21

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 16

Registration Number: NCT01211197

Locations: 🇩🇪
1276.5.1 Boehringer Ingelheim Investigational Site, Biberach, Germany

Efficacy and Safety of Empagliflozin (BI 10773) in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: BI 10773
Drug: Placebo

First Posted Date: 2010-09-28

Last Posted Date: 2014-06-17

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 499

Registration Number: NCT01210001

Locations: 🇺🇸
1245.19.10070 Boehringer Ingelheim Investigational Site, Irvine, California, United States
🇺🇸
1245.19.10161 Boehringer Ingelheim Investigational Site, Phoenix, Arizona, United States
🇺🇦
1245.19.75006 Boehringer Ingelheim Investigational Site, Lviv, Ukraine

and more 65 locations

LUX Lung Special Access Scheme Australia Named Patient Use (NPU)

Conditions: Carcinoma, Non-Small-Cell Lung

First Posted Date: 2010-09-27

Last Posted Date: 2016-11-10

Lead Sponsor: Boehringer Ingelheim

Registration Number: NCT01209650

Locations: 🇦🇺
1200.47.1 Boehringer Ingelheim Investigational Site, North Ryde, New South Wales, Australia

Safety, Tolerability, Pharmacokinetics and -Dynamics of Multiple Rising Oral Doses of BI 113823 in Patients Patients With Osteoarthritis of the Knee

Phase 1

Terminated

Conditions: Osteoarthritis

Interventions: Drug: BI 113823

First Posted Date: 2010-09-23

Last Posted Date: 2013-11-05

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 36

Registration Number: NCT01207973

Locations: 🇩🇪
1272.2.1 Boehringer Ingelheim Investigational Site, Muenchen, Germany

An Open Label Phase I Dose Escalation Trial of Intravenous BI 6727 (Volasertib)in Combination With Oral BIBW 2992 (Afatinib) in Patients With Advanced Solid Tumours

Phase 1

Completed

Conditions: Neoplasms

Interventions: Drug: BI 6727 + BIBW 2992

First Posted Date: 2010-09-22

Last Posted Date: 2019-02-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 57

Registration Number: NCT01206816

Locations: 🇧🇪
1230.20.32001 Boehringer Ingelheim Investigational Site, Bruxelles, Belgium
🇧🇪
1230.20.32003 Boehringer Ingelheim Investigational Site, Edegem, Belgium
🇧🇪
1230.20.32002 Boehringer Ingelheim Investigational Site, Gent, Belgium

A Phase I Trial to Investigate the Metabolism and Pharmacokinetics as Well as Safety and Tolerability of a Single Dose BI671800 HEA Administered as an Oral Solution of the Choline Salt in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 671800

First Posted Date: 2010-09-20

Last Posted Date: 2013-11-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 8

Registration Number: NCT01205373

Locations: 🇺🇸
1268.7.001 Boehringer Ingelheim Investigational Site, Madison, Wisconsin, United States

Telmisartan+Amlodipine Fixed Dose Combination in Hypertension

Phase 3

Completed

Conditions: Hypertension

Interventions: Drug: telmisartan+amlodipine fixed dose combination

First Posted Date: 2010-09-17

Last Posted Date: 2014-06-27

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 27

Registration Number: NCT01204398

Locations: 🇨🇳
1235.31.86001 Boehringer Ingelheim Investigational Site, Shanghai, China

Comprehensive Add on Study in Japan

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Linagliptin
Drug: Metformin

First Posted Date: 2010-09-17

Last Posted Date: 2014-03-28

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 574

Registration Number: NCT01204294

Locations: 🇯🇵
1218.78.037 Boehringer Ingelheim Investigational Site, Higashi Osaka, Osaka, Japan
🇯🇵
1218.78.026 Boehringer Ingelheim Investigational Site, Kasugai, Aichi, Japan
🇯🇵
1218.78.038 Boehringer Ingelheim Investigational Site, Kawachinagano, Osaka, Japan

and more 40 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy